%	O
%	O
TITLE	O

A	O
high	O
and	O
increasing	O
HPV	O
prevalence	B-Incidence_or_Prevalence
in	O
tonsillar	O
cancers	O
in	O
Eastern	B-Study_Location
Denmark	I-Study_Location
,	O
2000	B-Study_Time
-	I-Study_Time
2010	I-Study_Time
:	O
the	O
largest	O
registry	O
-	O
based	O
study	O
to	O
date	O
.	O

%	O
%	O
ABSTRACT	O

The	O
aim	O
was	O
to	O
explore	O
whether	O
the	O
incidence	B-Incidence_or_Prevalence
of	O
tonsillar	O
squamous	O
cell	O
carcinomas	O
(	O
TSCCs	O
)	O
increased	O
in	O
Eastern	B-Study_Location
Denmark	I-Study_Location
,	O
2000	B-Study_Time
-	I-Study_Time
2010	I-Study_Time
,	O
and	O
whether	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
could	O
explain	O
the	O
increase	O
,	O
and	O
to	O
assess	O
the	O
association	O
of	O
HPV	O
prevalence	B-Incidence_or_Prevalence
with	O
gender	O
,	O
age	O
,	O
and	O
origin	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
certainty	O
of	O
tonsillar	O
tumor	O
origin	O
)	O
.	O

We	O
applied	O
HPV	B-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
and	O
p16	O
immunohistochemistry	B-HPV_Lab_Technique
to	O
all	O
TSCCs	O
registered	O
in	O
the	O
Danish	O
Head	O
and	O
Neck	O
Cancer	O
Group	O
(	O
DAHANCA	O
)	O
and	O
in	O
the	O
Danish	O
Pathology	O
Data	O
Bank	O
(	O
nâ€‰=â€‰632	O
)	O
.	O

Pathologists	O
reviewed	O
and	O
subdivided	O
the	O
tumors	O
into	O
two	O
groups	O
:	O
specified	O
and	O
nonspecified	O
TSCCs	O
.	O

Approximately	O
10	O
%	O
of	O
HPV	O
-	O
positive	O
tumors	O
was	O
genotyped	O
by	O
amplicon	O
next	O
-	O
generation	O
sequencing	O
.	O

The	O
overall	O
crude	O
incidence	B-Incidence_or_Prevalence
of	O
TSCCs	O
increased	O
significantly	O
(	O
2	O
.	O
7	O
%	O
per	O
year	O
)	O
and	O
was	O
explained	O
by	O
an	O
increasing	O
incidence	B-Incidence_or_Prevalence
of	O
HPV	O
-	O
positive	O
TSCCs	O
(	O
4	O
.	O
9	O
%	O
per	O
year	O
)	O
.	O

The	O
overall	O
HPV	O
prevalence	B-Incidence_or_Prevalence
was	O
58	O
%	O
,	O
with	O
HPV16	O
being	O
the	O
predominant	O
HPV	O
type	O
.	O

In	O
multivariate	O
analysis	O
,	O
the	O
HPV	O
prevalence	B-Incidence_or_Prevalence
was	O
associated	O
with	O
age	O
(	O
<	O
55	O
vs	O
.	O
>	O
60	O
years	O
)	O
(	O
OR	O
,	O
1	O
.	O
72	O
;	O
95	O
%	O
CI	O
1	O
.	O
13	O
-	O
2	O
.	O

63	O
)	O
and	O
origin	O
(	O
nonspecified	O
vs	O
.	O
specified	O
TSCCs	O
)	O
(	O
OR	O
,	O
0	O
.	O
15	O
;	O
95	O
%	O
CI	O
0	O
.	O
11	O
-	O
0	O
.	O
22	O
)	O
.	O

The	O
association	O
of	O
HPV	O
prevalence	B-Incidence_or_Prevalence
with	O
origin	O
increased	O
over	O
time	O
in	O
specified	O
TSCCs	O
(	O
OR	O
per	O
year	O
,	O
1	O
.	O
10	O
;	O
95	O
%	O
CI	O
1	O
.	O
01	O
-	O
1	O
.	O

19	O
)	O
,	O
whereas	O
no	O
change	O
over	O
time	O
was	O
observed	O
among	O
nonspecified	O
TSCCs	O
(	O
OR	O
per	O
year	O
,	O
0	O
.	O
99	O
;	O
95	O
%	O
CI	O
0	O
.	O
90	O
-	O
1	O
.	O
08	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
observed	O
increase	O
in	O
the	O
number	O
of	O
HPV	O
-	O
positive	O
TSCCs	O
can	O
explain	O
the	O
increasing	O
number	O
of	O
TSCCs	O
in	O
Eastern	B-Study_Location
Denmark	I-Study_Location
,	O
2000	B-Study_Time
-	I-Study_Time
2010	I-Study_Time
.	O

HPV	O
prevalence	B-Incidence_or_Prevalence
was	O
associated	O
with	O
younger	O
age	O
(	O
<	O
55	O
years	O
)	O
and	O
a	O
high	O
certainty	O
of	O
tonsillar	O
tumor	O
origin	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Patients	O
and	O
tumor	O
samples	O

Danish	O
OPSCC	O
patients	O
are	O
referred	O
to	O
and	O
treated	O
at	O
regional	O
Head	O
and	O
Neck	O
Centers	O
at	O
University	O
Hospitals	O
.	O

Due	O
to	O
the	O
Danish	O
public	O
health	O
care	O
system	O
,	O
private	O
treatment	O
options	O
do	O
not	O
exist	O
for	O
patients	O
with	O
head	O
and	O
neck	O
cancer	O
.	O

Furthermore	O
,	O
it	O
is	O
very	O
rare	O
that	O
Danish	O
patients	O
move	O
to	O
other	O
Head	O
and	O
Neck	O
Centers	O
;	O
it	O
happens	O
only	O
in	O
unusual	O
cases	O
of	O
accumulation	O
of	O
patients	O
at	O
one	O
center	O
where	O
they	O
are	O
offered	O
earlier	O
treatment	O
at	O
another	O
center	O
.	O

All	O
Danish	O
residents	O
are	O
registered	O
in	O
the	O
computerized	O
Civil	O
Registration	O
System	O
with	O
a	O
unique	O
personal	O
identiﬁca	O
-	O
tion	O
number	O
(	O
PIN	O
)	O
.	O
29	O
The	O
PIN	O
is	O
used	O
in	O
all	O
national	O
regis	O
-	O
tries	O
,	O
facilitating	O
accurate	O
linkage	O
.	O

Using	O
the	O
PIN	O
as	O
a	O
key	O

Int	O
.	O

J	O
.	O

Cancer	O
:	O
136	O
,	O
2196–2203	O
(	O
2015	O
)	O
VC	O
2014	O
UICC	O

identiﬁer	O
,	O
we	O
linked	O
two	O
nationwide	O
Danish	O
registries	O
[	O
the	O
Danish	O
Head	O
and	O
Neck	O
Cancer	O
Group	O
(	O
DAHANCA	O
)	O
data	O
-	O
base	O
and	O
the	O
Danish	O
Pathology	O
Data	O
Bank	O
]	O
to	O
identify	O
and	O
validate	O
our	O
cohort	B-Study_Cohort
of	I-Study_Cohort
tonsillar	I-Study_Cohort
cancers	I-Study_Cohort
in	O
Eastern	B-Study_Location
Denmark	I-Study_Location
.	I-Study_Location

The	O
DAHANCA	O
collects	O
information	O
on	O
all	O
head	O
and	O
neck	O
cancer	O
patients	O
from	O
the	O
time	O
of	O
diagnosis	O
and	O
during	O
follow	O
-	O
up	O
The	O
Danish	O
Pathology	O
Databank	O
con	O
-	O
tains	O
data	O
on	O
all	O
pathoanatomical	O
examinations	O
done	O
in	O
Den	O
-	O
mark	O
,	O
reported	O
by	O
the	O
pathology	O
departments	O
through	O
an	O
online	O
,	O
real	O
-	O
time	O
system	O
.	O
30	O
First	O
,	O
we	O
identiﬁed	O
all	O
patients	O
diagnosed	O
with	O
tonsillar	O
cancer	O
in	O
the	O
Capital	O
Region	O
of	O
Den	O
-	O
mark	O
and	O
the	O
Region	O
of	O
Zealand	O
(	O
covering	O
ca	O
.	O
40	O
%	O
of	O
the	O
Danish	O
population	O
,	O
2	O
.	O
2	O
million	O
inhabitants	O
)	O
as	O
registered	O

in	O
the	O
DAHANCA	O
database	O
during	O
2000–2010	O
.	O

Second	O
,	O
we	O
linked	O
our	O
cohort	O
to	O
the	O
Danish	O
Pathology	O
Data	O
Bank	O
.	O

We	O
obtained	O
information	O
on	O
the	O
patients’	O
tumor	O
tissue	B-HPV_Sample_Type
and	O
col	O
-	O
lected	O
specimens	B-HPV_Sample_Type
.	I-HPV_Sample_Type

See	O
Supporting	O
Information	O
for	O
a	O
map	O
of	O
the	O
Danish	O
Regions	O
including	O
their	O
populations	O
.	O

TSCCs	O
rep	O
-	O
resent	O
ca	O
.	O
60	O
%	O
of	O
Danish	O
OPSCCs	O
.	O
1	O

The	O
study	O
was	O
conducted	O
according	O
to	O
the	O
Helsinki	O
Decla	O
-	O

ration	O
and	O
approved	O
by	O
the	O
Regional	O
Scientiﬁc	O
Ethical	O
Com	O
-	O
mittee	O
(	O
H	O
-	O
C	O
-	O
2008	O
-	O
080	O
)	O
and	O
the	O
Danish	O
Data	O
Protection	O
Agency	O
.	O

Review	O
of	O
histology	O

Specialized	O
head	O
and	O
neck	O
pathologists	O
,	O
according	O
to	O
our	O
author	O
list	O
,	O
validated	O
the	O
diagnoses	O
of	O
all	O
histological	O
speci	O
-	O
mens	O
,	O
assessed	O
the	O
expression	B-HPV_Lab_Technique
of	I-HPV_Lab_Technique
p16	I-HPV_Lab_Technique
by	I-HPV_Lab_Technique
IHC	I-HPV_Lab_Technique
in	O
the	O
tumor	O
slides	O
,	O
and	O
categorized	O
all	O
tumors	O
as	O
speciﬁed	O
TSCCs	O
(	O
STSCCs	O
)	O
or	O
nonspeciﬁed	O
TSCCs	O
(	O
NSTSCCs	O
)	O
.	O

p16	B-HPV_Lab_Technique
immunohistochemistry	I-HPV_Lab_Technique
.	I-HPV_Lab_Technique

Immunohistochemistry	B-HPV_Lab_Technique
for	I-HPV_Lab_Technique
p16	I-HPV_Lab_Technique
was	O
carried	O
out	O
on	O
formalin	O
-	O
ﬁxed	O
parafﬁn	O
-	O
embedded	O
(	O
FFPE	O
)	O
tissue	B-HPV_Sample_Type
sections	O
on	O
the	O
Ventana	O
BenchMark	O
ULTRA	O
platform	O
(	O
Roche	O
,	O
Basel	O
,	O
Switzerland	O
)	O
with	O
the	O
OptiView	O
Detection	O
Kit	O
(	O
Roche	O
)	O
and	O
the	O
p16	O
monoclonal	O
antibody	O
E6H4	O
(	O
Roche	O
)	O
,	O
according	O
to	O
standard	O
protocols	O
.	O

Based	O
on	O
p16	O
positivity	O
,	O
tumors	O
were	O
categorized	O
into	O
ﬁve	O
groups31	O
:	O
0	O
,	O
0	O
%	O
positive	O
tumor	O
cells	O
;	O
1	O
,	O
1–25	O
%	O
positive	O
tumor	O
cells	O
;	O
2	O
,	O
26–50	O
%	O
positive	O

tumor	O
cells	O
;	O
3	O
,	O
51–75	O
%	O
positive	O
tumor	O
cells	O
;	O
and	O
4	O
,	O
76–100	O
%	O
positive	O
tumor	O
cells	O
.	O

Tumors	O
in	O
group	O
4	O
(	O
76–100	O
%	O
p16	O
-	O
positive	O
tumor	O
cells	O
)	O
exhibiting	O
strong	O
diffuse	O
nuclear	O
and	O
cytoplasmic	O
staining	O
were	O
deﬁned	O
as	O
p16	O
-	O
positive	O
.	O
32	O

Division	O
of	O
tumors	O
into	O
“specified	O
TSCCs”	O
and	O
“nonspecified	O
TSCCs	O
.	O
”	O
Tumors	O
were	O
divided	O
into	O
STSCCs	O
and	O
NSTSCCs	O
based	O
on	O
a	O
combination	O
of	O
clinical	O
information	O
obtained	O
in	O
the	O
Danish	O
Pathology	O
Data	O
Bank	O
,	O
reported	O
by	O
the	O
clinician	O
who	O
performed	O
the	O
biopsy	O
,	O
and	O
review	O
of	O
tissue	B-HPV_Sample_Type
-	O
speciﬁc	O
structures	O
in	O
the	O
tumor	O
sections	O
.	O

Tumors	O
were	O
reclassiﬁed	O
as	O
STSCCs	O
if	O
they	O
exhibited	O
tonsillar	O
tissue	B-HPV_Sample_Type
(	O
tonsillar	O
crypts	O
and	O
tonsillar	O
lymphoid	O
tissue	B-HPV_Sample_Type
with	O
germinal	O
centers	O
)	O
in	O
the	O
biopsy	B-HPV_Sample_Type
section	I-HPV_Sample_Type
or	O
the	O
tumor	O
,	O
according	O
to	O
clinical	O
information	O
origi	O
-	O
nated	O
in	O
the	O
tonsils	O
.	O

Tumors	O
were	O
reclassiﬁed	O
as	O
NSTSCCs	O
if	O
they	O
did	O
not	O
exhibit	O
tonsillar	O
tissue	B-HPV_Sample_Type
,	I-HPV_Sample_Type
and	O
the	O
tumor	O
,	O
according	O

to	O
the	O
clinical	O
information	O
,	O
originated	O
in	O
oropharyngeal	O
T	O
-	O

sites	O
other	O
than	O
the	O
tonsil	O
.	O

NSTSCCs	O
were	O
often	O
tumors	O
involving	O
multiple	O
oropharyngeal	O
T	O
-	O
sites	O
.	O

In	O
case	O
of	O
doubt	O
,	O
further	O
clinical	O
information	O
was	O
obtained	O
from	O
the	O
patient’s	O
ﬁle	O
or	O
from	O
analysis	O
of	O
additional	O
tumor	O
sections	O
.	O

None	O
of	O
the	O
tumors	O
was	O
assessed	O
as	O
arising	O
from	O
the	O
base	O
of	O
the	O
tongue	O
.	O

Thirty	O
-	O
six	O
tumor	O
biopsies	B-HPV_Sample_Type
(	O
6	O
%	O
of	O
total	O
)	O
contained	O
only	O
tumor	O
tissue	B-HPV_Sample_Type
,	O
and	O
clinical	O
information	O
on	O
T	O
-	O
site	O
was	O
insufﬁcient	O
.	O

These	O
were	O
reclassiﬁed	O
as	O
NSTSCCs	O
.	O

The	O
group	O
of	O
pathologists	O
held	O
regular	O
meetings	O
to	O
secure	O
a	O
uniform	O
classiﬁcation	O
of	O
STSCCs	O
versus	O
NSTSCCs	O
.	O

HPV	O
DNA	O
analysis	O

The	O
HPV	O
DNA	O
analysis	O
was	O
blinded	O
with	O
regard	O
to	O
the	O
review	O
of	O
histology	O
.	O

Each	O
FFPE	O
tumor	O
specimen	B-HPV_Sample_Type
was	O
handled	O
at	O
the	O
Department	O
of	O
Pathology	O
according	O
to	O
standard	O
PCR	B-HPV_Lab_Technique
protocol	O
.	O

For	O
every	O
ﬁve	O
tumor	O
specimens	B-HPV_Sample_Type
,	O
one	O
negative	O
con	O
-	O
trol	O
(	O
consisting	O
of	O
skeletal	O
muscle	O
)	O
was	O
cut	O
and	O
processed	O
the	O
same	O
way	O
as	O
the	O
tumor	O
samples	B-HPV_Sample_Type
,	O
to	O
exclude	O
cross	O
-	O
contamination	O
in	O
the	O
DNA	O
isolation	O
and	O
the	O
HPV	B-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
analysis	I-HPV_Lab_Technique
.	I-HPV_Lab_Technique

DNA	O
isolation	O
and	O
HPV	B-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
and	O
HPV	O
genotyping	O
were	O
performed	O
at	O
the	O
Center	O
for	O
Genomic	O
Medicine	O
,	O
Rigshospita	O
-	O
let	O
:	O
DNA	O
was	O
isolated	O
from	O
four	O
10	O
-	O
mm	O
sections	O
with	O
the	O
QIAamp	O
DNA	O
FFPE	O
Tissue	O
Kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
according	O
to	O
the	O
instruction	O
manual	O
.	O

We	O
performed	O
HPV	B-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
general	I-HPV_Lab_Technique
primers	I-HPV_Lab_Technique
GP51	I-HPV_Lab_Technique
/	I-HPV_Lab_Technique
GP61	I-HPV_Lab_Technique
.	I-HPV_Lab_Technique
33	I-HPV_Lab_Technique
The	O
DNA	O
quality	O
of	O
specimens	B-HPV_Sample_Type
with	O
a	O
negative	O
GP51	B-HPV_Lab_Technique
/	I-HPV_Lab_Technique
GP61	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
was	O
validated	O
with	O
PCR	B-HPV_Lab_Technique
for	O
the	O
housekeeping	O
gene	O
GAPDH	O
,	O
based	O
on	O
an	O
amplicon	O
of	O
approximately	O
200	O
base	O
pairs	O
(	O
bp	O
)	O
.	O

HPV	O
genotyping	O

We	O
performed	O
amplicon	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
on	O
34	O
blindly	O
selected	O
GP51	O
/	O
GP61	O
positive	O
samples	B-HPV_Sample_Type
(	O
approximately	O
10	O
%	O
of	O
the	O
positive	O
samples	B-HPV_Sample_Type
)	O
.	O

Fifty	O
-	O
nanogram	O
quantities	O
of	O
DNA	O
of	O
each	O
sample	B-HPV_Sample_Type
were	O
pooled	O
.	O

The	O
pooled	O
amplicons	O
were	O
puriﬁed	O
with	O
1	O
,	O
2x	O
sample	O
volume	O
Agentcourt	O
AMPure	O
XP	O
beads	O
(	O
Beckman	O
Coulter	O
,	O
Brea	O
,	O
CA	O
)	O
,	O
which	O
excluded	O
DNA	O
fragments	O
of	O
fewer	O
than	O
100	O
bp	O
,	O
followed	O
by	O
amplicon	O
size	O
analysis	O
on	O
a	O
Bioanalyzer	O
(	O
Agilent	O
Technolo	O
-	O
gies	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
.	O

Next	O
we	O
performed	O
emulsion	B-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
according	I-HPV_Lab_Technique
to	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
emPCR	I-HPV_Lab_Technique
Ampliﬁcation	I-HPV_Lab_Technique
Method	I-HPV_Lab_Technique
Manual	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
Lib	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
A	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
GS	I-HPV_Lab_Technique
Junior	I-HPV_Lab_Technique
Titanium	I-HPV_Lab_Technique
Series	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Roche	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
,	O
and	O
the	O
amplicons	O
were	O
sequenced	O
on	O
the	O
GS	O
Junior	O
platform	O
(	O
Roche	O
)	O
according	O
to	O
the	O
manufacturer’s	O
Sequencing	O
Methods	O
Manual	O
,	O
GS	O
Jun	O
-	O
ior	O
Titanium	O
Series	O
.	O

We	O
analyzed	O
the	O
variants	O
in	O
a	O
GS	O
Amplicon	O
Variance	O

Analyzer	O
(	O
Roche	O
)	O
,	O
and	O
the	O
identiﬁed	O
sequences	O
were	O
blasted	O
in	O
a	O
NCBI	O
Nucleotide	O
Blast	O
program	O
ov	O
)	O
to	O
determine	O
HPV	O
types	O
.	O

Statistical	O
analysis	O

Statistical	O
analysis	O
was	O
done	O
in	O
IBM	O
SPSS	O
19	O
(	O
IBM	O
SPSS	O
,	O
Chicago	O
,	O
IL	O
)	O
and	O
SAS	O
(	O
SAS	O
9	O
.	O
3	O
,	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
)	O
.	O

The	O
Pearson	O
Chi	O
-	O
square	O
test	O
was	O
used	O
to	O
compare	O
included	O

Int	O
.	O

J	O
.	O

Cancer	O
:	O
136	O
,	O
2196–2203	O
(	O
2015	O
)	O
VC	O
2014	O
UICC	O

Figure	O
1	O
.	O

Overview	O
of	O
exclusions	O
and	O
final	O
study	O
population	O
.	O

Abbre	O
-	O
viations	O
:	O
DAHANCA	O
,	O
Danish	O
Head	O
and	O
Neck	O
Cancer	O
Group	O
;	O
SCC	O
,	O
squamous	O
cell	O
carcinoma	O
;	O
n	O
,	O
number	O
of	O
patients	O
.	O

patients	O
with	O
excluded	O
patients	O
according	O
to	O
age	O
,	O
gender	O
,	O
and	O
year	O
of	O
diagnosis	O
,	O
as	O
well	O
as	O
proportions	O
of	O
HPV1	O
/	O
p16	O
-	O
and	O
HPV	O
-	O
/	O
p161	O
in	O
STSCCs	O
versus	O
NSTSCCs	O
.	O

Cohen’s	O
kappa	O
was	O
calculated	O
to	O
assess	O
the	O
correlation	O
of	O
HPV	O
DNA	O
PCR	B-HPV_Lab_Technique
and	O
p16	B-HPV_Lab_Technique
IHC	I-HPV_Lab_Technique
,	O
including	O
95	O
%	O
conﬁdence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
.	O

Pois	O
-	O
son	O
regression	O
analysis	O
was	O
used	O
to	O
estimate	O
the	O
average	O
annual	O
percentage	O
change	O
(	O
APC	O
)	O
in	O
the	O
incidence	B-Incidence_or_Prevalence
of	O
all	O
TSCCs	O
as	O
well	O
as	O
in	O
groups	O
according	O
to	O
HPV	O
status	O
.	O

The	O

Table	O
1	O
.	O

Comparison	O
of	O
tonsillar	O
cancers	O
in	O
Eastern	O
Denmark	O
(	O
2000–	O
2010	O
)	O
included	O
and	O
excluded	O
in	O
the	O
study	O

Abbreviations	O
:	O
DAHANCA	O
,	O
Danish	O
Head	O
and	O
Neck	O
Cancer	O
Group	O
;	O
no	O
.	O
,	O
number	O
of	O
patients	O
;	O
%	O
,	O
percentage	O
of	O
total	O

HPV	O
prevalence	B-Incidence_or_Prevalence
according	O
to	O
gender	O
,	O
age	O
,	O
and	O
origin	O
was	O
investigated	O
in	O
a	O
multivariate	O
logistic	O
regression	O
analysis	O
,	O
with	O
associations	O
presented	O
as	O
odds	O
ratios	O
(	O
OR	O
)	O
with	O
95	O
%	O
CI	O
.	O

Var	O
-	O
iables	O
were	O
mutually	O
adjusted	O
and	O
furthermore	O
adjusted	O
for	O
year	O
of	O
diagnosis	O
(	O
continuous	O
)	O
.	O

